Executive Summary
Megasys Biotek recognizes that once a product enters the market, new information may emerge that can influence its benefit–risk profile. Continuous and thorough evaluation of data generated through pharmacovigilance activities is essential to ensure the safe use of all products. By proactively identifying and mitigating risks, effective pharmacovigilance strengthens patient safety and enables timely communication of critical information to healthcare professionals and medicine users.

To achieve this, Megasys Biotek has established a robust pharmacovigilance system designed to:

• Detect and promptly collect reports of any adverse effects associated with its products
• Ensure expert analysis of safety data
• Disseminate findings appropriately to enhance drug safety and minimize adverse reactions

The company maintains ongoing collaboration with expert consultants and regulatory authorities to uphold the highest safety standards. Safety evaluation is a continuous process at Megasys Biotek, reflecting its commitment to vigilance and patient well-being.

Megasys Biotek is dedicated to embedding good pharmacovigilance practices across all operations, with a strong focus on improving patient care and public health by:

• Contributing to the ongoing assessment of product benefits, risks, harms, and effectiveness
• Promoting education and training in pharmacovigilance
• Ensuring effective communication of safety information to the medical community and the public
• Encouraging rational and safe use of medicines to enhance overall health outcomes

Please refer to the pharmacovigilance policy provided below to familiarize yourself with our procedures.

Click here👉 Adverse Drug Reaction (ADR) Form

Megasys Biotek is committed to manufacturing high‑quality medicines and maintaining global regulatory compliance. Please report any adverse reactions using the form below. These reports are critical for continuous evaluation of the benefit–risk profile of our products.

Click here👉 Adverse Drug Reaction (ADR) Form

Who Can Report

• Healthcare professionals: Doctors, dentists, nurses, pharmacists, patients, etc.
• Non‑healthcare individuals: Patients, relatives, friends, or any concerned person.

Confidentiality:
The patient’s identity is strictly protected and kept confidential. The company will not disclose the reporter’s identity in response to any public request.